Uveitis associated with juvenile idiopathic arthritis
https://doi.org/10.21508/1027-4065-2019-64-2-30-37
Abstract
Rheumatoid uveitis is a serious problem in rheumatology and ophthalmology due to the peculiarities of the disease – an undistinguished beginning, chronic course and a high incidence of disabling complications. The article analyzes various data on the development and nature of uveitis in children with juvenile idiopathic arthritis. The authors describe the analysis of the results of various studies of this disease. They consider the features and results of treatment of children with rheumatoid uveitis using genetically engineered biological drugs.
About the Authors
L. A. Galstyan
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
E. S. Zholobova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
S. N. Chebysheva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
A. V. Meleshkina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
V. A. Seraya
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
O. Yu. Loskutova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Heiligenhaus A., Heinz C., Edelsten C., Kotaniemi K., Minden K. Review for Disease of the Year: Epidemiology of Juvenile Idiopathic Arthritis and its Associated Uveitis: The Probable Risk Factors. Ocular Immunol Inflamm 2013; 21(3): 180–191.DOI: 10.3109/09273948.2013.791701
2. Carvounis P.E., Herman D.C., Cha S., Burke J.P. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefe’s Arch Clin Exper Ophthalmol 2006; 244: 281–290. DOI: 10.1186/1745-6215-15-14
3. Saurenmann R.K., Rose J.B., Tyrrell P., Feldman B.M., Laxer R.M., Schneider R., et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: Ethnicity as a risk factor. Arthritis Rheum 2007; 56: 1974–1984. DOI: 10.1002/art.22709
4. Heiligenhaus A., Niewerth M., Ganser G., Heinz C., Minden K. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015–1019. DOI: 10.1093/rheumatology/kem053
5. Kotaniemi K., Kautiainen H., Karma A., Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis. A prospective study. Ophthalmology 2001; 108: 2071–2075. DOI: 10.1016/j.jaapos.2008.03.007
6. Brewerton D.A., Caffrey M., Nicholls A., Walters D., James D.C. Acute anterior uveitis and HL-A 27. Lancet 1973; 2: 994–996.
7. Angeles-Han S.T., McCracken C., Yeh S., Jang S.R., Jenkins K., Cope S. et al. HLA Associations in a Cohort of Children With Juvenile Idiopathic Arthritis With and Without Uveitis. Investigat Ophthalmol Visual Sci 2015; 56(10): 6043–6048. DOI: 10.1186/s12969-015-0018-8
8. Murray K.J., Moroldo M.B., Donelly P., Prahalad S., Passo M.H., Giannini E.H., Glass D.N. Age-specific effects of juvenile rheumatoid arthritis – associated HLA alleles. Arthritis Rheum 1999; 42: 1843–1853. DOI: 10.1167/iovs.15-17168.
9. Zholobova E.S., Galstyan L.A., Nicolaeva M.N., Loskutova O.Yu., Starikova A.V., Denisova E.V. Efficacy of adalimumab for treatment of juvenile idiopathic arthritis. Pediatria 2014; 3: 67–71. (in Russ) DOI: 10.15690/vsp.v14i6.1475
10. Sen E.S., Dick A.D., Ramanan A.V. Uveitis associated with juvenile idiopathic arthritis. Nature Rev Rheumatol 2015; 11(6): 338–348. DOI: 10.1038/nrrheum.2015.20
11. Drozdova E.A., Yadykina E.V. Significance of interleukin-17 in the development of uveitis in children with juvenile idiopathic arthritis (JIA). Vestnik OGU 2015; 12(187): 64–70. (in Russ)
12. Walscheid K., Hennig M., Heinz C., Wasmuth, S., Busch M., Bauer D. et al. Correlation between disease severity and presence of ocular autoantibodies in juvenile idiopathic arthritis associated uveitis. Invest Ophthalmol Vis Sci 2014; 55: 3447–3453. DOI: 10.1167/iovs.13-13444
13. Deschenes J., Murray P.I., Rao N.A., Nussenblatt R.B. International Uveitis Study Group International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm 2008; 16(1): 1–2. DOI: 10.1080/09273940801899822
14. Clarke S.L., Sen E.S., Ramanan A.V. Juvenile idiopathic arthritis-associated uveitis. Pediatric Rheumatol Online J 2016; 14(27). DOI: 10.1186/s12969-016-0088-2
15. Yadykina E.V., Drozdova E.A., Ivanovskaya E.A. Predisposing risk factors for the development of uveitis related to juvenile idiopathic arthritis. Meditsinskii vestnik Bashkortostana 2014; 2: 190–193. (in Russ)
16. Katargina L.A., Arhipova L.T. Uveitis: pathogenetic immunosuppressive therapy. Tver’: Triada, 2004; 100. (in Russ)
17. British Society for Paediatric and Adolescent Rheumatology, Royal College of Ophthalmology. Guidelines for screening for Uveitis in Juvenile idiopathic arthritis. 2006; 55: 373–377. DOI: 10.118/sl12969-017-0185-x
18. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of Uveitis Nomenclature (SUN) Working Group Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140(3): 509–516. DOI: 10.1056/NEJMc1603618
19. Tappeiner C., Heinz C., Roesel M., Heiligenhaus A. Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis. Acta Ophthalmol 2011; 89(6): 521–527. DOI: 10.1111/j.1755-3768.
20. Holland G.N. A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007; 105: 344–364.
21. Heinz C., Schumacher C., Roesel M., Heiligenhaus A. Elevated intraocular pressure in uveitis associated with juvenile idiopathic arthritis-associated uveitis, often detected after achieving inactivity. Brit J Ophthalmol 2012; 96: 140–141. DOI: 10.1136/bjophthalmol-2011-300731
22. Ducos de Lahitte G., Terrada C., Tran T., Cassoux N., Le Hoang P., Kodjikian L. et al. Maculopathy in uveitis of juvenile idiopathic arthritis: coherence tomography study. Brit J Ophthalmol 2008; 92(8): 1159. DOI: 10.1136/bjo.2007.120675
23. Hawkins M.J., Dick A.D., Lee R.J., Ramanan A.V., Carreño E., Guly C.M. et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol 2016; 61(2): 197–210. DOI: 10.1016/j.survophthal.2015.10.005
24. Rheumatology. E.L. Nasonov, V.A. Nasonova (eds). Moscow: GEOTAR-Media, 2008; 720. (in Russ)
25. Hoeve M., Kalinina Ayuso V., Schalij-Delfos N.E., Los L.I., Rothova A., de Boer J.H. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Brit J Ophthalmol 2012; 96: 852–856. DOI: 10.1371/journal.pone.0164312
26. Drozdova E.A., Yadykina E.V. Clinical parallels of uveitis and arthritis course in patients with juvenile idiopathic arthritis. Vestnik SMU 2014; 1–2: 41–44. (in Russ)
27. Davies K., Cleary G., Foster H., Hutchinson E., Baildam E. British Society of Paediatric and Adolescent Rheumatology BSPAR standards of care for children and young people with juvenile idiopathic arthritis. Rheumatology 2010; 49(7): 1406–1408. DOI: 10.1186/s12969-017-0170-4
28. Merida S., Palacios E., Navea A. New Immunosuppressive Therapies in Uveitis Treatment. Int J Mol Sci 2015; 16(8): 18778–18795. DOI: 10.3390/ijms160818778
29. La Mattina K.C., Goldstein D.A. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol 2017; 13(3): 181–188. DOI: 10.1080/1744666X.2017.1288097
30. Vazquez-Cobian L.B., Flynn T., Lehman T.J. Adalimumab therapy for childhood uveitis. J Pediatr 2006; 149(4): 572–575. DOI: 10.1016/j.jpeds.2006.04.058
31. Biester S., Deuter C., Michels H., Haefner R., Kuemmerle-Deschner J., Doycheva D. et al. Adalimumab in the therapy of uveitis in childhood. Brit J Ophthalmol 2007; 91: 319–324. DOI: 10.1136/bjo.2006.103721
32. Ramanan A.V., Dick A.D., McKay A., Jones A., Williamson P., Compeyrot-Lacassagne S. et al. A randomized controlled trial of the clinical effectiviness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis. Arthritis Rheum 2015; 67(10). DOI: 10.1186/s12969-016-0088-2
33. Alekseeva E.I., Mitenko E.V., Valieva S.I., Bzarova T.M., Denisova R.V., Isaeva K.B. et al. Efficacy and safety of pediatric juvenile idiopathic arthritis and uveitis treatment with adalimumab. Voprosy sovremennoi pediatrii 2012; 1: 111–118. (in Russ) DOI: 10.15690/vsp.v11i1.141
34. Kel’cev V.A., Grebyonkina L.I., Moiseeva E.D. Comparative evaluation of the efficacy and safety of treatment using adalimumab in combination with methotrexate and methotrexate monotherapy in children with polyarticular juvenile idiopathic arthritis in combination with uveitis. Voprosy sovremennoi pediatrii 2014; 6: 60–66. (in Russ) DOI: 10.15690/vsp.v14i6.1475
35. Gajdar E.V., Kostik M.M., Dubko M.F., Masalova V.V., Snegireva L.S., Isupova E.A. et al. The Efficiency of Adalimumab in Cases of Chronic Methotrexate-Resistant Juvenile Idiopathic Arthritis-Associated Anterior Uveitis: Retrospective Case Series Study. Pediatricheskaya farmakologiya 2016; 4: 340–344. (in Russ) DOI: 10.15690/pf.v13i4.1605
36. PavhunT.V., Shishkina I.K., Pishchulina I.V., Yusupova M.K., Gorshkova L.V. Efficacy of use TNF-α inhibitor adalimumab in a female patient with chronic uveitis in the onset of juvenile idiopathic arthritis. Pediatricheskaya farmakologiya 2016; 1: 54–58. (in Russ) DOI: 10.15690/pf.v13i1.1516
37. Isaeva K.B., Alekseeva E.I., Denisova R.V., Sleptsova T.V., Bzarova Т.М., Valieva S.I. et al. Experience of the adalimumab application for the patient with early debut of juvenile idiopathic arthritis and uveitis. Voprosy sovremennoi pediatrii 2014; 4: 156–161. (in Russ)
38. Kahn P., Weiss M., Imundo L., Levy D.M. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 113: 860–864. DOI: 10.5402/2012/765380
39. Ayranci O., Tugal-Tutkun I., Kasapcopur O. Infliximab treatment for refractory childhood uveitis. 9th International Congress IOIS, 2007; OP10-05. DOI: 10.4274/tjo.09581
40. Neroev V.V., Katargina L.A., Denisova E.V., Starikova A.V., Lyubimova N.V. Efficacy of genetically engineered biological agents in the treatment of uveitis associated with rheumatic diseases in children. Nauchno-prakticheskaya revmatologiya 2012; 4(53): 91–95. (in Russ)
41. Zannin M.E., Birolo C., Gerloni V., Miserocchi E., Pontikaki I., Paroli M.P. et al. Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry. J Rheumatol 2013; 40(1): 74–79. DOI: 10.3899/jrheum.120583
42. Smith J.A., Thompson D.J., Whitcup S.M., Suhler E., Clarke G., Smith S. et al. A randomized, placebo-controlled, doublemasked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Care Res 2005; 53: 18–23. DOI: 10.1002/art.20904
43. Kakkassery V., Mergler S., Pleyer U. Anti-TNF-alpha Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment. Curr Eye Res 2010; 35: 751–756. DOI: 10.3109/02713683.2010.486520
44. Schmeling H., Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005; 44: 1008–1011. DOI: 10.1093/rheumatology/keh658
45. Foeldvari I., Becker I., Horneff G. Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in pediatric rheumatology registry. Arthritis Care Res 2015; 67(11): 1529–1535. DOI: 10.1002/acr.22613
46. Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis. A case report. J Rheumatol 2008; 35(9): 1897–1898. DOI: 10.1007/s40674-017-0057-z
47. Elhai M., Deslandre C.J., Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res 2011; 63: 307–308. DOI: 10.1002/acr.20359
48. Alpigiani M.G., Salvati P., Vannati M., Bagnis A., Papadia M., Traverso C.E. et al. Abatacept for severe anti TNF-alpha refractory JIA-associated uveitis: a case report. Clin Exp Rheumatol 2011; 29: 410. DOI: 10.1016/j.semarthrit.2015.05.010
49. Zulian F., Balzarin M., Falcini F., Martini G., Alessio M., Cimaz R. et al. Abatacept for Severe Anti-Tumor Necrosis Factor alpha Refractory Juvenile Idiopathic Arthritis-Related Uveitis. Arthritis Care Res 2010; 62: 821–825. DOI: 10.1002/acr.20115
50. Tappeiner C., Miserocchi E., Bodaghi B., Kotaniemi K., Mackensen F., Gerloni V. et al. Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol 2015; 42(4): 706–711. DOI: 10.3899/jrheum.140410
51. Galstyan L.A., Zholobova E.S., Starikova A.V., Denisova E.V. Efficacy of abatacept therapy in a patient with juvenile idiopathic arthritis and bilateral uveitis. Voprosy sovremennoi pediatrii 2016; 3: 307–310. (in Russ) DOI: 10.15690/vsp.v15i3.1569
52. Tappeiner C., Mesquida M., Adan A., Anton J., Ramanan A.V., Carreno E. et al. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol 2016, 43(12): 2183–2188. DOI: 10.3899/jrheum.160231
53. Bou R., Adan A., Borras F., Bravo B., Calvo I., De Inocencioet J. et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int 2015; 35(5): 777–785. DOI: 10.1007/s00296-015-3231-3
54. Lerman M.A., Lewen M.D., Kempen J.H., Monte D.M. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160(1): 193–200. DOI: 10.1016/j.ajo.2015.04.016
55. Heiligenhaus A., Miserocchi E., Heinz C., Gerloni V., Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011; 50: 1390–1394. DOI: 10.4274/tjo.09581
56. Sen H.N., Levy-Clarke G., Faia L.J., Li Z., Yeh S., Barron K.S. et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009; 148: 696–703. DOI: 10.1016/j.ajo.2009.06.003
57. Hayward K., Wallace C.A. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res& Therapy 2009; 11: 216. DOI: 10.1186/ar2619
58. Salugina S.О., Katargina L.A., Starikova A.V. Rheumatological diseases and eyes lesions in children. Nauchno-prakticheskaya revmatologiya 2004; 42(1): 78–81. (in Russ) DOI: 10.14412/1995-4484-2004-1389
Review
For citations:
Galstyan L.A., Zholobova E.S., Chebysheva S.N., Meleshkina A.V., Seraya V.A., Loskutova O.Yu. Uveitis associated with juvenile idiopathic arthritis. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2019;64(2):30-37. (In Russ.) https://doi.org/10.21508/1027-4065-2019-64-2-30-37
Views:
1296
Email this article 